2024 AD/PD™ conference presented new data on lecanemab's unique binding properties with lower adverse events.

BioArctic and Eisai presented new data on lecanemab (Leqembi®) at the 2024 AD/PD™ conference. BioArctic's founder, Professor Lars Lannfelt, highlighted lecanemab's unique binding properties, preferentially binding soluble and insoluble amyloid-beta (Aβ) aggregates. Lecanemab's lower binding to CAA may explain the lower adverse event ARIA seen in comparison to other antibodies, according to the data presented.